Barcelona, June 26th, 2020.
MERLION is a physician initiated, prospective, non-randomized multi-center trial.
Investigating the safety and efficacy of the treatment with luminor DCB and angiolite BTK DES in TASC C and D Tibial Occlusive disease, in patients with critical limb ischemia.
The 6 months clinical outcomes of MERLION Trial were presented at VIVA 2020, at the late breaking trial session, by Dr TY Tang (Singapore).
MERLION 6-month outcomes
MERLION 6-month outcomes show a 100% technical success, with a 4.5% bailout stenting for severe flow limiting dissection using angiolite BTK and a Primary Patency of 78.9% at 6-month.
Freedom from clinically driven TLR was 91.7% while the amputation free survival (AFS) was 88%, both at 6-month.
Dr Tang concluded that “luminor DCB is safe and efficacious, in treating highly complex infra-popliteal atherosclerotic lesions in challenging CLTI patients” and he added that “luminor is associated with highly satisfactory acute technical success, 6-month target lesion patency and AFS.”
To learn more about the trial visit: https://ivascular.global/clinical-trials/merlion-trial/
Endovascular Today article: https://bit.ly/3dQklBD